Production of Alpha Emitters for Targeted Alpha Therapy

被引：29
|
作者：
Morgenstern, A. [1 ]
Abbas, K. [2 ]
Bruchertseifer, F. [1 ]
Apostolidis, C. [1 ]
机构：
[1] European Commiss, Joint Res Ctr, Inst Transuranium Elements, POB 2340, D-76125 Karlsruhe, Germany
[2] European Commiss, Joint Res Ctr, Inst Hlth & Consumer Protect, I-21020 Ispra, VA, Italy
来源：
CURRENT RADIOPHARMACEUTICALS | 2008年 / 1卷 / 03期
关键词：
Targeted alpha therapy; alpha emitter; production; uranium-230; thorium-227; thorium-226; actinium-225; radium-223; bismuth-213; lead-212; bismuth-212; astatine-211; terbium-149;
D O I：
10.2174/1874471010801030135
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including (225) Ac / Bi-213, U-230 / Th-226, Th-227 / Ra-223, Pb-212 / Bi-212, At-211 and Tb-149. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
引用
收藏
页码：135 / 143
页数：9
相关论文
共 50 条
  • [31] Overview of current available alpha emitters for alpha radiation therapy and treatment of cancers.
    Mojtahedi, Alireza
    Ghesani, Nasrin
    Howell, Roger
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [32] ALPHA EMITTERS - REPLY
    WILEY, JS
    AMERICAN SCIENTIST, 1975, 63 (06) : 619 - 619
  • [33] IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals
    Jalilian, A. R.
    Kleynhans, J.
    Bouziotis, P.
    Bruchertseifer, F.
    Chakraborty, S.
    De Blois, E.
    Denecke, M.
    Elboga, U.
    Gizawyi, M.
    Horak, C.
    Jang, J.
    Korde, A.
    Majkowska-Pilip, A.
    Mdlophane, A.
    Ocampo-Garcia, B.
    Selivanova, S. V.
    Starovoitova, V.
    Wojdowska, W.
    Zeevaart, J. R.
    Radchenko, V.
    NUCLEAR MEDICINE AND BIOLOGY, 2025, 144
  • [34] Production of U-230/Th-226 for targeted alpha therapy
    Morgenstern, A.
    Abbas, K.
    Bruchertseifer, F.
    Lebeda, O.
    Simonelli, F.
    Stursa, J.
    Apostolidis, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S260 - S260
  • [35] Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
    Nelson, Bryce J. B.
    Wilson, John
    Andersson, Jan D.
    Wuest, Frank
    PHARMACEUTICALS, 2023, 16 (11)
  • [36] Targeted Alpha Therapy with Bi-213
    Morgenstern, Alfred
    Bruchertseifer, Frank
    Apostolidis, Christos
    CURRENT RADIOPHARMACEUTICALS, 2011, 4 (04) : 295 - 305
  • [37] Targeted Alpha Therapy: Current Clinical Applications
    Guerra Liberal, Francisco D. C.
    O'Sullivan, Joe M.
    McMahon, Stephen J.
    Prise, Kevin M.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (06) : 404 - 417
  • [38] Advances in targeted alpha therapy for prostate cancer
    De Vincentis, G.
    Gerritsen, W.
    Gschwend, J. E.
    Hacker, M.
    Lewington, V.
    O'Sullivan, J. M.
    Oya, M.
    Pacilio, M.
    Parker, C.
    Shore, N.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1728 - 1739
  • [39] Editorial: Targeted alpha particle therapy in oncology
    Bruland, Oyvind Sverre
    Larsen, Roy Hartvig
    Baum, Richard Paul
    Juzeniene, Asta
    FRONTIERS IN MEDICINE, 2023, 10
  • [40] Targeted alpha particle therapy for uveal melanoma
    Tafreshi, Narges K.
    Delva, Nella C.
    Tichacek, Christopher J.
    Doligalski, Michael L.
    Pandya, Darpan N.
    Bhatt, Nikunj B.
    Kil, HyunJoo
    Budzevich, Mikalai M.
    Ruiz, Epifanio
    Wadas, Thaddeus J.
    McLaughlin, Mark L.
    Morse, David L.
    CANCER RESEARCH, 2017, 77
12345